SEARCH - DEVELOP - INNOVATE
Thanks to a deep understanding of metabolic disorders and physiopathology, LNC Therapeutics develops gut microbiota directed drugs to tackle obesity and its associated cardiometabolic diseases
LNC Therapeutics is working on the first gut microbiota directed drugs initiated by a medical nutrition product clinical outcomesOur solutions for metabolic diseases
Who benefits
Patients
Public Health
Pharmaceutical groups
Human gut microbiome is a revolutionary field presenting numerous promising opportunities in obesity management
Latest Posts:
More
about us
about us
From the creation of LNC Therapeutics, the founders shared the same vision: to address the issue of obesity by acting on its fundamental causes
Learn morePublications
In order to be on the cutting edge of scientific research and innovation, we select and analyse key scientific publications and materials
Discover our selection
Find out moreObésité, des alternatives à...
La connaissance de notre flore intestinale, de nos gènes et de notre cerveau laissent entrevoir de...
Six trends we spotted at...
VivaTech is a festival of French and European technology, featuring a blend of big brands and...
LNC Therapeutics Appoints New...
On April 17, 2018, LNC Therapeutics, a French biotech company, announced the appointment of Dr....
La pépite LNC Therapeutics...
Prometteuse jeune pousse bordelaise dans le domaine de la santé, auteure d'une des plus belles...